Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details Narrative)

v3.21.2
NOTES PAYABLE (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 28, 2020
Nov. 30, 2020
Nov. 30, 2019
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Debt Instrument, Unamortized Discount       $ 2,262,388   $ 2,262,388   $ 2,262,388
Interest Expense, Debt       686,000 $ 460,000 2,016,000 $ 460,000  
Fair Value, Inputs, Level 3 [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Secured debt       18,551,000   18,551,000   18,029,000
Lenders [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Debt Instrument, Unamortized Discount       2,262,000   2,262,000    
Insurance Policy [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Prepaid expenses       101,042   101,042   $ 1,010,000
Loan Agreement [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Notes payable   $ 909,375 $ 963,514          
Monthly principal and interest payments   $ 103,112 $ 109,413          
Monthly loan payments term   nine-month period nine-month period          
Annual interest rate   4.89% 5.25%          
Final payment       $ 1,190,000   $ 1,190,000    
Loan Agreement [Member] | K2 HealthVentures LLC [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Annual interest rate       8.50%   8.50%    
Secured debt $ 50,000,000     $ 21,190,000   $ 21,190,000    
Debt description The loan matures on August 1, 2024 and the Company is obligated to make interest only payments for the first 24 months and then interest and equal principal payments for the next 24 months. Interest accrues at a variable annual rate equal to the greater of (i) 8.5% and (ii) the rate of interest noted in The Wall Street Journal, Money Rates section, as the “Prime Rate” plus 5.25%, in each case, subject to a step-down of 25 basis points upon the funding of the second tranche.              
Debt maturity date Aug. 01, 2024              
Debt conversion amount           $ 5,000,000    
Debt conversion per share       $ 9.40   $ 9.40    
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 86,206              
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 6.96              
Proceeds from Warrant Exercises $ 472,000              
Proceeds from prepayment and default features 546,000              
Debt issuance cost 1,244,000              
Final payment 1,190,000              
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche One [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Secured debt 20,000,000              
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche Two [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Secured debt 20,000,000              
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche Three [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Secured debt $ 10,000,000              
Default Loan Agreement [Member] | K2 HealthVentures LLC [Member]                
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]                
Annual interest rate       5.00%   5.00%    
Debt maturity date           Aug. 01, 2024